eligibility_summary
Inclusion: BASECAMP-1 enrolled with HLA‑A02:01 LOH, successful apheresis/PBMC for Tmod CAR‑T, unresectable/metastatic CEA+ CRC/NSCLC/PANC/other solid tumor, measurable disease (>1 cm CT), prior required therapy, adequate organ function, ECOG 0–1, life ≥3 mo, agrees to follow-up. Exclusion: disease suitable for local/standard therapy, prior allo SCT/solid organ transplant, therapy <3 w or <3 HL, RT <28 d, cardiac event <6 mo, PE/DVT <3 mo, home O2, pregnant/breastfeeding, no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
A2B530 is an autologous, genetically engineered Tmod CAR T-cell therapy tested after lymphodepletion for CEA+ solid tumors (CRC, NSCLC, pancreatic, others) with tumor-specific loss of HLA-A02. Mechanism: a logic-gated, dual-receptor design—an activator CAR targets carcinoembryonic antigen (CEA), while a blocker receptor recognizes HLA-A02 on normal cells. T cells activate only in CEA+ cells lacking HLA-A02 (AND-NOT gating), aiming to spare normal CEA+ tissues (e.g., gut). Targets: CEA-expressing tumor cells with HLA-A02 loss of heterozygosity, pathway: CAR-mediated T-cell cytotoxicity exploiting tumor HLA loss as a self-protection switch. Companion diagnostic: xT-Onco with HLA-LOH NGS assay to confirm eligibility. Phase 1 defines a safe/recommended dose, Phase 2 evaluates antitumor efficacy and on-target/off-tumor protection.